The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease / 生理学报
Acta Physiologica Sinica
;
(6): 663-669, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-777216
ABSTRACT
The employment of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in the treatment of diabetes mellitus and diabetic kidney disease (DKD) becomes a hot topic in recent years. Compared with traditional glucose-lowering drugs, SGLT-2 inhibitors present distinctive advantages in renal and cardiovascular protection. The mechanisms for renal protection include attenuating glomerular hyperfiltration, lowering serum uric acid, alleviating tubular lesions and regulating intrarenal renin-angiotensin-aldosterone system (RAAS) dysfunction. In addition, the lowering blood pressure, blunting blood glucose fluctuation, increasing insulin sensitivity, optimizing energy metabolism and body fat distribution account for the cardiovascular protective effects of SGLT-2 inhibitors. However, their potential adverse reactions and safety concerns should be carefully addressed in clinical usage.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacología
/
Ácido Úrico
/
Diabetes Mellitus Tipo 2
/
Nefropatías Diabéticas
/
Quimioterapia
/
Transportador 2 de Sodio-Glucosa
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
/
Hipoglucemiantes
Límite:
Humanos
Idioma:
Chino
Revista:
Acta Physiologica Sinica
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS